Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.

"CONFLICT OF INTEREST Dr. Alonso is employed by OWL Metabolomics. Dr. Anstee is the coordinator of the EU IMI‐2 LITMUS consortium. He received grants from, consults for, and is on the speaker’s bureau for Allergan. He received grants from and consults for AstraZeneca, Boehringer Ingelheim, Intercept, Novartis, and Pfizer. He consults for and is on the speakers’ bureau for BMS, Genfit SA, and Gilead. He consults for 89 Bio, Abbvie, Akero, Altimentiv, Alitimmune, Axcella, Blade, BNN Cardio, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd, Galmed, Genentech, Grunthal, HistoIndex, Indalo, Inventiva, IQVIA, Janssen, Johnson & Johnson, Madrigal, MedImmune, Medpace, Merck, Metacrine, NGMBio, North Sea Therapeutics, Novo Nordisk, PathAI, Poxel, ProSciento, Raptor Pharma, Roche, Servier, Shionogi, Terns, The Medicines Company, and Viking Therapeutics. He is on the speakers’ bureau for Abbott Laboratories, Clinical Care Options, Falk, Fishawack, Integritas Communications, Kenes, and Medscape. He received grants from GlaxoSmithKline and Glympse Bio. He receives royalties from Elsevier. Dr. Arretxe is employed by OWL Metabolomics. Dr. Banales advises OWL Metabolomics. Dr. Bugianesi consults for and received grants from Gilead. She consults for NovoNordisk, Lilly, and Merck. Dr. Crespo is on the speakers’ bureau for Intercept and Shionogui. He received grants from Gilead and AbbVie. Dr. Cusi consults for Arrowhead, AstraZeneca, 89 Bio, Lilly, Madrigal, and Quest. He advises Sagimet, Sonic Incytes, and Terns. He received grants from Echosens, Inventiva, Novo, Poxel, and Labcorp. Dr. Iruarrizaga‐Lejarreta is employed by OWL Metabolomics. Dr. Hayardeny owns stock in and is employed by Galmed. Dr. Mato consults and advises Abbott. He owns stock in, consults for, and advises OWL Metabolomics. He consults for Galmed. Dr. mayo is employed by OWL Metabolomics. Mr. Martinez‐Arranz is employed by OWL Metabolomics. Mrs. Mincholé is employed by OWL Metabolomics. Dr. Noureddin owns stock in and received grants from Viking. He advises and received grants from Gilead, Madrigal, and Pfizer. He consults for Perspectum. He advises 89 Bio, Altimmune, CohBar, Cytodyn, Intercept, Novo Nordisk, Blade, EchoSens, Fractyl, NorthSea, Terns, Siemens, and Roche. He received grants from Allergan, BMS, Galmed, Galectin, Genfit, Conatus, Enanta, Novartis, Shire, and Zydus. He owns stock in Anaetos and Rivus Pharma."

"Funding information"